Mycobacterial carrier and antitumour activity of the combination: BCG-cyclophosphamide.
Immuno-chemical studies of various BCG components show that the anti-tumour effect of BCG plus cyclophosphamide is attributed to the interaction between two bacterial fractions and the cytotoxic drug, cyclophosphamide(CY). One of the bacterial fraction is a chemically-well-defined peptidoglycopeptide fraction(PGLF) with immuno-stimulating activity and the other is a bacterial residue (BR) completely devoid of immuno-stimulating activity. Nevertheless, BR, a powerful adsorbant, was found to be a "mycobacterial carrier" of both the active bacterial molecule (PGLF) and the cytotoxic drug (CY).
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000032:analysis*; D001500:BCG Vaccine / Q000008:administration & dosage / Q000032:analysis*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D006020:Glycopeptides / Q000302:isolation & purification; D051379:Mice; D008815:Mice, Inbred Strains
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D006020:Glycopeptides; D003520:Cyclophosphamide